Skip to content
Menu

Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.

Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.

Read at benzinga.com